Role of subantihypertensive dose of lisinopril in regression of hypertensive left ventricle hypertrophy

Left ventrical hypertrophy [LVH]: an independent cardiovascular risk factor is present in a significant number of hypertensive patients. The reversal of LHV is a desirable therapeutic goal in the treatment of hypertension because the prognosis of the patients, whose treatment has led to the regression in cardiac hypertrophy is markdly better than that of patients in whom regression in cardiac hypertrophy fails to be achieved. Lisinopril, an ACE inhibitor has been shown to alter the anatomy of heart positively, even used in subantihypertensive dose, suggesting the mortant role of RAS, in the onset and progression of LVH, whereas moduretic almost did not produce any change in the size of the ventricle despite favourable effect on BP